| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22065 |
| Drug | Olaparib |
| Brand | Lynparza® |
| Indication | As monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 26/10/2022 |
| Rapid review completed | 20/10/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 26/10/2022 |
| Pre-submission consultation with Applicant | 13/12/2022 |
| Full submission received from Applicant | 27/09/2023 |
| Preliminary review sent to Applicant | 09/05/2024 |
| NCPE assessment re-commenced | 06/06/2024 |
| Follow-up to preliminary review sent to Applicant | 05/07/2024 |
| NCPE assessment re-commenced | 11/07/2024 |
| Factual accuracy sent to Applicant | 20/08/2024 |
| NCPE assessment re-commenced | 27/08/2024 |
| NCPE assessment completed | 24/09/2024 |
| NCPE assessment outcome | The NCPE recommends that olaparib be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
